NCT06737419View on ClinicalTrials.gov

Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice

CompletedOBSERVATIONAL
Enrollment

175

Participants

Timeline

Start Date

June 9, 2021

Primary Completion Date

February 5, 2024

Study Completion Date

February 5, 2024

Conditions
Multiple Sclerosis
Trial Locations (1)

07936

Novartis, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY